Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Size: px
Start display at page:

Download "Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview"

Transcription

1 Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April

2 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics company based in Oxford Focused on delivering improved solutions for accurate disease analysis and early disease detection Self-financing, with headline revenues of 10m Operating in 30 countries worldwide, with ambitious US plans Poised for period of significant value creation, based on strong market position and rapid advances in the molecular medicine sector Experienced management, originating from premier companies including Amersham (GE Healthcare), GSK, Affymetrix 2

3 The molecular medicine landscape A rapidly evolving revolution in healthcare 3

4 The molecular medicine landscape OGT s competitive advantage Next Generation Sequencing Biomarkers Accurate, meaningful results Array technologies Sample preparation Companion diagnostics Consumer genomics Genomic medicine DNA testing 4

5 Premier league customers 5

6 Balanced business model Delivering revenue growth & significant investment upside Accurate disease analysis Early disease detection Genomic products and services Meaningful results Internal biomarker programmes 6

7 Balanced business model Delivering revenue growth & significant investment upside Accurate disease analysis Early disease detection Constitutional arrays Prostate cancer Molecular testing arrays Cancer arrays Genomic products and services Cancer panels Sequencing services Array services Meaningful results Colorectal cancer Internal biomarker programmes Lupus Non-invasive prenatal screening 7

8 Genomic products and services Accurate disease analysis CytoSure Cytogenetic Products for the research into genetic disease Technology: Microarrays and analysis software Applications: Constitutional disorders (e.g. learning disorders) Haematological cancer Genefficiency Genomic Services for research into genetic disease Technologies: DNA microarrays Next generation sequencing Applications: All genetic diseases 8

9 $Millions Cytogenetics market Forecast for rapid growth Market growth driven by: Increasing adoption of molecular techniques (e.g. microarrays) Oncology applications Growing public awareness and demand for personalised medicine * Global Industry Analysts, Inc

10 CytoSure What is CytoSure? A microarray (glass slide) with thousands of expertly designed DNA fragments (probes) printed on the surface Coupled with sophisticated labelling and interpretative software to aid analysis What does it do? Allows comparison of normal and disease samples to accurately detect learning disorders and haematological cancers Why is it different? Enables much easier and more accurate interpretation of data 10

11 CytoSure Extensive product range Constitutional genetics research Developmental delay (e.g., autism) Cancer cytogenetics research Leukaemia, myeloma Molecular genetics research Heart disease, diabetes, Duchenne muscular dystrophy Arrays CytoSure ISCA/ISCA SNP CytoSure Syndrome Plus CytoSure Aneuploidy CytoSure Haematological Cancer + SNP CytoSure Molecular Testing CytoSure DMD Reagents CytoSure Genomic DNA Labelling Kits Automation Full automation options Software CytoSure Interpret Software Meaningful results 11

12 CytoSure The complete solution for clinical genetics research 12

13 CytoSure Strong foundations for significant growth CytoSure sold to 30 countries High-profile customer base Comprehensive product range Class-leading analysis software New US office CytoSure development plan Expand product range: Pre-natal, pre-implantation genetic screening, cancer, companion products Acquisition of new technology to develop additional tests 13

14 Genomic services market Rapidly evolving and growing sector Market size: Genomics market estimated to be $6.5b* Next Generation Sequencing (NGS) is estimated to be $1.1b with double digit growth* Market growth driven by: Rigorous quality control required by large genomic studies and clinical research samples Rapid and straightforward interpretation of large volumes of data into meaningful results Quick turnaround times Genomics market estimated to be $6.5b* (NGS) is estimated to be $1.1b with double digit growth* $1.1b* * DeciBio,

15 Sequencing to understand disease Hitting the headlines 15

16 Genefficiency What is Genefficiency? World-leading accurate, high-throughput genomic services What does it do? Utilises the latest genomic technologies (e.g. microarrays and next generation sequencing) and analysis techniques to identify the genetic causes of disease Why is it different? High throughput over 2,000 samples/week Higher quality unique quality management system & accreditations Expert data analysis rapid identification of causative mutations 16

17 Genefficiency Ideally positioned to capture significant share of genomic services market Global sales High-profile customer base Awarded 3 high profile grants: June 2011: 1.2m TSB tumour profiling service March 2012: 1.5m EU infectious disease March 2012: 920k EU predisposition to infection Genefficiency development plans: Expand available platforms and applications Drive the implementation of clinical sequencing 17

18 Internal biomarker programmes Early disease detection Biomarker discovery pipeline Patent protected portfolio Proprietary technology Leverage links with research institutions Experienced team Development focus Areas of unmet medical need Large potential markets Primarily cancer and autoimmune disease Balanced development strategy 18

19 OGT s biomarker discovery pipeline Feasibility study Sample recruitment Biomarker discovery Biomarker validation Clinical validation Colorectal cancer Second most frequent cancer in the developed world Current tests low specificity and poor patient compliance OGT biomarker panel delivers sensitivity and specificity >90% Promising data in detection of adenomas and early-stage cancer Prostate cancer Most common male cancer ~260,000 deaths per annum Current test very low specificity (~30%) resulting in unnecessary treatment 30 million tests annually in US alone (market size approx. $3 billion) OGT panel sensitivity and specificity >80%; ability to measure aggressiveness Lupus Autoimmune disease affecting 1 in 500 African Americans, 1 in 2,500 Europeans Current test low specificity 57% OGT biomarker panel delivers specificity of 89% 19

20 OGT s biomarker commercialisation strategy Colorectal cancer Requires extensive sales network More rapid sales achieved via partnership Out-license Prostate cancer Significant CLIA laboratory service opportunity Aggressiveness rather than screening application Specialist customer base Develop in-house Lupus Specialist autoimmune diagnostic market Smaller market size Out-license 20

21 million OGT Group: financial position Commercial Revenues* F2013 CytoSure Services Private, self-financing company Sustained revenue growth CAGR of >85% pa Growth Feb YTD +45% * For financial years ending 30 September, excludes patent revenues and royalties. 21

22 OGT growth strategy Strong Strong foundation Sustained organic growth Acceleration foundation Addressing high growth markets New product launches to drive revenue and margin growth Expansion into new territories and adjacent markets Higher value business models Selective acquisitions and investments Focus on cytogenetics research Cancer arrays NGS disease panels US salesforce Asia expansion Pre-natal testing Pre-implantation genetic screening Cancer biomarkers Non-invasive prenatal screening (NIPS) Cytogenetics companies Biomarker validation 22

23 The molecular medicine landscape Growing market capitalisations and high multiple transactions Peer group companies Multi million/billion transactions in the molecular medicine space Sept 2012 Acquired by Illumina for $100m Market Cap: $588.6m NASDAQ:SQNM April 2012 Rejected bid from Roche for $6.7.bn May 2012 Acquired by Agilent for $2.2bn Feb 2012 Predicted value at IPO bn Market Cap: $620.41M NASDAQ April 2012 Acquired by Quest Diagnostics for $740m Dec 2011 Acquired by LabCorp for $85m 23

24 Summary World-class potential, with strong reputation and increasing share in large and growing molecular medicine space Global sales, with ambitious expansion plans Premier league customer base Experienced management team with proven ability Well financed with risk diversified business model 24

25 Innovative genetics research and biomarker solutions to advance molecular medicine CytoSure and Genefficiency NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures 25

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 DIAGNOSTICS BUSINESS ANALYSIS SERIES: TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298 By ADAMS BUSINESS ASSOCIATES MAY 2014. May 2014 ABA 298 1 Technologies, Products & Services

More information

Fishing for variants in the deep end of the gene pool: OGT s custom bait designs

Fishing for variants in the deep end of the gene pool: OGT s custom bait designs Fishing for variants in the deep end of the gene pool: OGT s custom bait designs Jolyon Holdstock, Simon Hughes and Daniel Swan Abstract Oxford Gene Technology (OGT) has extensive expertise in probe design

More information

Next Generation Sequencing Informatics Markets

Next Generation Sequencing Informatics Markets Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To

More information

Standard #2 If you right click on a Agenda slide in the left navigation bar you can choose between other slide layouts. TIP:

Standard #2 If you right click on a Agenda slide in the left navigation bar you can choose between other slide layouts. TIP: Annual Report 2014 Agenda 2 Full year results FY 2014 Exiqon Life Sciences Exiqon Diagnostics Corporate objective and investment case Financial calendar and outlook for 2015 Full year results 2014 - Q4

More information

U.S. Clinical Laboratory and Pathology Testing 2013-2015:

U.S. Clinical Laboratory and Pathology Testing 2013-2015: U.S. Clinical Laboratory and Pathology Testing 2013-2015: Market Analysis, Trends, and Forecasts Now more than ever, it s critical to understand the industry at a macro level. Prepare your organization

More information

The Molecular Diagnostic Market and development of personalized molecular tests

The Molecular Diagnostic Market and development of personalized molecular tests The Molecular Diagnostic Market and development of personalized molecular tests Dr. Iris Simon Sr. Director Research & Development, Agendia NV, Amsterdam NL and Irvine CA Agendia - Who are we Molecular

More information

Automated DNA sequencing 20/12/2009. Next Generation Sequencing

Automated DNA sequencing 20/12/2009. Next Generation Sequencing DNA sequencing the beginnings Ghent University (Fiers et al) pioneers sequencing first complete gene (1972) first complete genome (1976) Next Generation Sequencing Fred Sanger develops dideoxy sequencing

More information

TOP 10 TRENDS IN HEALTHCARE, MEDICAL. HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer

TOP 10 TRENDS IN HEALTHCARE, MEDICAL. HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer TOP 10 TRENDS IN HEALTHCARE, MEDICAL AND PHARMACEUTICAL INDUSTRY HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer KPJSeremban Specialist Hospital KPJ SEREMBAN SPECIALIST HOSPITAL Presented by : Hj Abd

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

Craig Hallum Conference Investor Presentation

Craig Hallum Conference Investor Presentation Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements

More information

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO

Photocure ASA. Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Brilliance in photodynamic technology TM Photocure ASA Exclusive global Licence Agreement for Lumacan with Salix Pharmaceuticals, Inc. 20 October 2010 Kjetil Hestdal, President & CEO Agreement with Salix

More information

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri)

ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,

More information

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH

VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH VALORIZZAZIONE DEI RISULTATI DELLA RICERCA ACCADEMICA E COLLABORAZIONE CON REALTA INDUSTRIALI FARMACEUTICHE BIOTECH Lucia Faccio, Direttore Sviluppo Ricerca Fondazione Telethon Why should academia transfer

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Sequencing and microarrays for genome analysis: complementary rather than competing?

Sequencing and microarrays for genome analysis: complementary rather than competing? Sequencing and microarrays for genome analysis: complementary rather than competing? Simon Hughes, Richard Capper, Sandra Lam and Nicole Sparkes Introduction The human genome is comprised of more than

More information

Sequencing power for every scale. Systems for every application, for every lab.

Sequencing power for every scale. Systems for every application, for every lab. Sequencing power for every scale. Systems for every application, for every lab. Proven sequencing technology. Accelerate your research. Achieve your next breakthrough. What started as novel Illumina chemistry,

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012!

Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012! Avacta Group plc Innovation for global health Interim Results 25th April 2012 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company

More information

DNA Sequencing and Personalised Medicine

DNA Sequencing and Personalised Medicine DNA Sequencing and Personalised Medicine Mick Watson Director of ARK-Genomics The Roslin Institute PERSONALISED MEDICINE What is personalised medicine? Personalized Medicine refers to the tailoring of

More information

European Society of Human Genetics Ad hoc committee for the accreditation of clinical laboratory geneticists

European Society of Human Genetics Ad hoc committee for the accreditation of clinical laboratory geneticists European Society of Human Genetics Ad hoc committee for the accreditation of clinical laboratory geneticists Clinical Laboratory Genetics as an EU-recognized specialist profession Aims and objectives for

More information

Predictive Breast Cancer Gene Testing

Predictive Breast Cancer Gene Testing Predictive Breast Cancer Gene Testing XX US Analysis and Market Forecasts XX XXX / Published XXX GDME1009CFR / Published February 2013 Executive Summary Predictive Breast Cancer Gene Testing: Key Metrics

More information

Medicare Coverage of Genomic Testing

Medicare Coverage of Genomic Testing Medicare Coverage of Genomic Testing Louis B. Jacques, MD Director, DID/CAG/OCSQ With acknowledgements to Jeff Roche, MD Social Security Act 1862(a)(1)(A) Notwithstanding any other provision of this title,

More information

CollabRx, Inc. (NasdaqCM: CLRX) Southern California Investor Conference August 8, 2013. Informing Next Generation Healthcare

CollabRx, Inc. (NasdaqCM: CLRX) Southern California Investor Conference August 8, 2013. Informing Next Generation Healthcare CollabRx, Inc. (NasdaqCM: CLRX) Southern California Investor Conference August 8, 2013 Informing Next Generation Healthcare Safe Harbor This presentation and the accompanying commentary include forward-looking

More information

What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives

What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives What does the career involve? Explore family histories to identify risks Reducing risks

More information

Creating the Ecosystem for Taking Genetics from Bench to Bedside in a Developing Country: A Personal Experience from Sri Lanka

Creating the Ecosystem for Taking Genetics from Bench to Bedside in a Developing Country: A Personal Experience from Sri Lanka Creating the Ecosystem for Taking Genetics from Bench to Bedside in a Developing Country: A Personal Experience from Sri Lanka Prof. Vajira H. W. Dissanayake MBBS, PhD, FNASSL Professor and Medical Geneticist

More information

Autoimmune Technologies, LLC - Product Pipeline Analysis

Autoimmune Technologies, LLC - Product Pipeline Analysis Brochure More information from http://www.researchandmarkets.com/reports/1957464/ Description: Summary Autoimmune Technologies, LLC (Autoimmune) is a biomedical company, based in the US. The company develops

More information

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Roland Diggelmann, COO Roche Diagnostics Bad Ragaz, 16 Jan 2015 Business model & strategy Q3 2014 overview Major products, launches and newsflow Building a leading sequencing

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Building Commercial Software. It has to work 100% of the time.

Building Commercial Software. It has to work 100% of the time. Building Commercial Software It has to work 100% of the time. Presenters SPI Software: Jeff Wilder: VP Customer Services Steve Schmidt: CFO Preclara: Jack Karabees: CEO U Innovation Bob Williamson: Entrepreneur

More information

Genomic Medicine Education Initiatives of the College of American Pathologists

Genomic Medicine Education Initiatives of the College of American Pathologists Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical

More information

Strategic Plan 2011-2016

Strategic Plan 2011-2016 Strategic Plan 2011-2016 approved by the Board of Trustees on 14 July 2011 revised May 2012 Contents Our Vision, our Mission 3 Our values 4 Introduction from the Chief Executive 5 Strategic direction 6

More information

World-leading expertise in Gene and Cell Therapy

World-leading expertise in Gene and Cell Therapy Worldleading expertise in Gene and Cell Therapy Jefferies Healthcare Conference New York, June 2015 Disclaimer The information contained in this presentation is being supplied and communicated to you on

More information

Genomic medicine in Australia. Professor Warwick Anderson Chief Executive Officer National Health and Medical Research Council

Genomic medicine in Australia. Professor Warwick Anderson Chief Executive Officer National Health and Medical Research Council Genomic medicine in Australia Professor Warwick Anderson Chief Executive Officer National Health and Medical Research Council This presentation 1. NHMRC s role funding research and translation 2. Genetic/genomic

More information

Directorate Medical Operations Patients and Information Nursing Policy Commissioning Development

Directorate Medical Operations Patients and Information Nursing Policy Commissioning Development 100,000 Genome Project NHS Genomic Medicine Centre Selection Prospectus July 2014 NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information Nursing Policy Commissioning

More information

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:

More information

CGH Microarray Solutions for Genome-Wide Genetic Analysis

CGH Microarray Solutions for Genome-Wide Genetic Analysis Microarray Solutions for Genome-Wide Genetic Analysis Custom & Catalog Microarrays High Quality Data CALL OR LEARN MORE AT: 1-800-227-9770 www.agilent.com/genomics For Research Use Only. Not for use in

More information

How to Conquer a Chromosome Abnormality What is microarray analysis?

How to Conquer a Chromosome Abnormality What is microarray analysis? University of Texas Health Science Center at San Antonio, Department of Pediatrics The Chromosome 18 Clinical Research Center Special points of interest: Microarray Analysis Agilent Technologies Microarray

More information

Cloud Computing And Pharma: A Prescription For Success. How and why this critical technology will change the industry. kellyservices.

Cloud Computing And Pharma: A Prescription For Success. How and why this critical technology will change the industry. kellyservices. Cloud Computing And Pharma: A Prescription For Success How and why this critical technology will change the industry kellyservices.us Contents Introduction Introduction / 3 01 Streamlining Operations and

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

The National Institute of Genomic Medicine (INMEGEN) was

The National Institute of Genomic Medicine (INMEGEN) was Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the

More information

Leading Genomics. Diagnostic. Discove. Collab. harma. Shanghai Cambridge, MA Reykjavik

Leading Genomics. Diagnostic. Discove. Collab. harma. Shanghai Cambridge, MA Reykjavik Leading Genomics Diagnostic harma Discove Collab Shanghai Cambridge, MA Reykjavik Global leadership for using the genome to create better medicine WuXi NextCODE provides a uniquely proven and integrated

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

Molecular diagnostics is now used for a wide range of applications, including:

Molecular diagnostics is now used for a wide range of applications, including: Molecular Diagnostics: A Dynamic and Rapidly Broadening Market Molecular diagnostics is now used for a wide range of applications, including: Human clinical molecular diagnostic testing Veterinary molecular

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Human Genome Organization: An Update. Genome Organization: An Update

Human Genome Organization: An Update. Genome Organization: An Update Human Genome Organization: An Update Genome Organization: An Update Highlights of Human Genome Project Timetable Proposed in 1990 as 3 billion dollar joint venture between DOE and NIH with 15 year completion

More information

Global Clinical Laboratory Testing Market Report: 2011 Edition

Global Clinical Laboratory Testing Market Report: 2011 Edition Brochure More information from http://www.researchandmarkets.com/reports/1725375/ Global Clinical Laboratory Testing Market Report: 2011 Edition Description: Clinical testing, which is a significant component

More information

GE s Technology and Services

GE s Technology and Services s Technology and Services Analyst Meeting May 4, 2006 Healthcare Healthcare Overview Vishal Wanchoo President & CEO, Healthcare IT 2 / Title or job number Healthcare business model Differentiate with technology

More information

European registered Clinical Laboratory Geneticist (ErCLG) Core curriculum

European registered Clinical Laboratory Geneticist (ErCLG) Core curriculum (February 2015; updated from paper issued by the European Society of Human Genetics Ad hoc committee for the accreditation of clinical laboratory geneticists, published in February 2012) Speciality Profile

More information

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010 Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices Response from Cancer Research UK to the Commission August 2010 1. Cancer Research UK (CR-UK) 1 is leading the world in finding

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

Bertelsmann Education Strategy

Bertelsmann Education Strategy Bertelsmann Education Strategy Group strategy Four strategic directions to transform business portfolio for sustainable growth; Education identified as strategic growth sector Target portfolio characteristics

More information

For personal use only

For personal use only ASX ANNOUNCEMENT 13 September 2011 Investor presentation at Rodman & Renshaw Annual Global Investment Conference in New York Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that the Company

More information

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours:

More information

G E N OM I C S S E RV I C ES

G E N OM I C S S E RV I C ES GENOMICS SERVICES THE NEW YORK GENOME CENTER NYGC is an independent non-profit implementing advanced genomic research to improve diagnosis and treatment of serious diseases. capabilities. N E X T- G E

More information

SCHEDULE 2 THE SERVICES

SCHEDULE 2 THE SERVICES SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. Service Commissioner Lead Provider Lead Period Date of Review E01/Sb NHS Genomic Laboratory Services 1. Population Needs 1.1

More information

Genetic diagnostics the gateway to personalized medicine

Genetic diagnostics the gateway to personalized medicine Micronova 20.11.2012 Genetic diagnostics the gateway to personalized medicine Kristiina Assoc. professor, Director of Genetic Department HUSLAB, Helsinki University Central Hospital The Human Genome Packed

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

Using genetic biomarkers to pre-identify oncology patients for clinical trials

Using genetic biomarkers to pre-identify oncology patients for clinical trials White paper Quintiles Vantage Point Quintiles helped develop or commercialize all of the Top 30 bestselling oncology products of 2014 Oncology pre-profiling: Using genetic biomarkers to pre-identify oncology

More information

Delivering the power of the world s most successful genomics platform

Delivering the power of the world s most successful genomics platform Delivering the power of the world s most successful genomics platform NextCODE Health is bringing the full power of the world s largest and most successful genomics platform to everyday clinical care NextCODE

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group JP Morgan Milan Investor Forum October 1, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System White Paper Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System Abstract: This paper describes QIAGEN s philosophy and process for developing

More information

Executive summary. Current prenatal screening

Executive summary. Current prenatal screening Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests

More information

Delivering real Information Management solutions that result in better, more efficient healthcare.

Delivering real Information Management solutions that result in better, more efficient healthcare. Delivering real Information Management solutions that result in better, more efficient healthcare. For more than 30 years, we have helped companies overcome challenges and identify opportunities to achieve

More information

Acquisition of. Special Investor Presentation

Acquisition of. Special Investor Presentation Acquisition of Special Investor Presentation October 21, 2015 Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section

More information

The 100,000 genomes project

The 100,000 genomes project The 100,000 genomes project Tim Hubbard @timjph Genomics England King s College London, King s Health Partners Wellcome Trust Sanger Institute ClinGen / Decipher Washington DC, 26 th May 2015 The 100,000

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

the central lab of choice for investigative sites and sponsors www.labconnectllc.com

the central lab of choice for investigative sites and sponsors www.labconnectllc.com the central lab of choice for investigative sites and sponsors www.labconnectllc.com Overview The LabConnect difference. LabConnect begins by developing a uniquely tailored laboratory services plan for

More information

Quarterly cash flow and activities report 30 June 2015

Quarterly cash flow and activities report 30 June 2015 Quarterly cash flow and activities report 30 June 2015 Genetic Signatures (ASX: GSS) is pleased to report on its activities for the quarter ended 30 June 2015. Highlights: Continued growth in sales of

More information

Biomarker-based diagnostics. Andras Apjok, CEO. Budapest, 17 February 2015 Innovation is GREAT Britain

Biomarker-based diagnostics. Andras Apjok, CEO. Budapest, 17 February 2015 Innovation is GREAT Britain Biomarker-based diagnostics Andras Apjok, CEO Budapest, 17 February 2015 Innovation is GREAT Britain Introduction: MDR and disease focus MDQuest is a spin off company of SOLVO Biotechnology (Hungary) MDQUEST

More information

ELITech Group - Product Pipeline Analysis

ELITech Group - Product Pipeline Analysis Brochure More information from http://www.researchandmarkets.com/reports/2351170/ ELITech Group - Product Pipeline Analysis Description: Summary The Elitech Group (Elitech Group) is a medical device company,

More information

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association 6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising

More information

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative

More information

Healthcare Reform Opens Up Middle-Market Opportunities

Healthcare Reform Opens Up Middle-Market Opportunities WWW.IBISWORLD.COM April 2013 1 April 2013 By IBISWorld Analysts Douglas Kelly & Anna Son A changing healthcare landscape and increasing demand are spurring potential deal opportunities in related industries.

More information

Global Clinical Laboratory Testing Market Report: 2012 Edition

Global Clinical Laboratory Testing Market Report: 2012 Edition Brochure More information from http://www.researchandmarkets.com/reports/2165640/ Global Clinical Laboratory Testing Market Report: 2012 Edition Description: Clinical laboratory testing market is one of

More information

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion...

Background and Company Performance... 3. Industry Challenges... 3. Product Family Attributes and Business Impact... 3. Conclusion... Contents Background and Company Performance... 3 Industry Challenges... 3 Product Family Attributes and Business Impact... 3 Conclusion... 5 Significance of Product Leadership... 6 Understanding Product

More information

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success

shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a

More information

Introducing. The Austell Graduate Recruitment Programme. in conjunction with. The Austell Academy GRADUATE OVERVIEW PHARMACEUTICALS

Introducing. The Austell Graduate Recruitment Programme. in conjunction with. The Austell Academy GRADUATE OVERVIEW PHARMACEUTICALS Introducing The Austell Graduate Recruitment Programme in conjunction with The Austell Academy GRADUATE OVERVIEW PHARMACEUTICALS AIM OF THE PROGRAMME WHAT IS THE AUSTELL GRADUATE RECRUITMENT PROGRAMME?

More information

Navigating England s clinical research infrastructure. How NOCRI helps simplify access to accelerate discoveries

Navigating England s clinical research infrastructure. How NOCRI helps simplify access to accelerate discoveries Navigating England s clinical research infrastructure How NOCRI helps simplify access to accelerate discoveries 2» The National Institute for Health Research (NIHR) Clinical Research Network recruited

More information

Automated Lab Management for Illumina SeqLab

Automated Lab Management for Illumina SeqLab Automated Lab Management for Illumina SeqLab INTRODUCTION Whole genome sequencing holds the promise of understanding genetic variation and disease better than ever before. In response, Illumina developed

More information

Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture

Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture HY 2013: Roche Group highlights HY 2013 performance Strong Pharma performance, driven by US; solid growth for Diagnostics 12% core EPS

More information

Becker Muscular Dystrophy

Becker Muscular Dystrophy Muscular Dystrophy A Case Study of Positional Cloning Described by Benjamin Duchenne (1868) X-linked recessive disease causing severe muscular degeneration. 100 % penetrance X d Y affected male Frequency

More information

Health Care Worldwide

Health Care Worldwide Health Care Worldwide Barclays European High Yield and Leveraged Finance Conference October 30, 2014 London Barclays European High Yield and Leveraged Finance Conference, October 30, 2014 Copyright Page

More information

The Digital Biology TM. Company. Targeted DNA Sequencing Solutions It Pays To Be On Target

The Digital Biology TM. Company. Targeted DNA Sequencing Solutions It Pays To Be On Target The Digital Biology TM Company Targeted DNA Sequencing Solutions It Pays To Be On Target Proven Platform RainDance TM Technologies is pioneering digital biology and powering ground-breaking human genetics

More information

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London

Health Care Worldwide. Citi - European Credit Conference September 24, 2015 - London Health Care Worldwide Citi - European Credit Conference September 24, 2015 - London Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties.

More information

Nazneen Aziz, PhD. Director, Molecular Medicine Transformation Program Office

Nazneen Aziz, PhD. Director, Molecular Medicine Transformation Program Office 2013 Laboratory Accreditation Program Audioconferences and Webinars Implementing Next Generation Sequencing (NGS) as a Clinical Tool in the Laboratory Nazneen Aziz, PhD Director, Molecular Medicine Transformation

More information

Empower your lab. Preimplantation genetic screening solutions.

Empower your lab. Preimplantation genetic screening solutions. Empower your lab. Preimplantation genetic screening solutions. Leading preimplantation genetic screening (PGS) solutions. Improve IVF success rates by optimizing embryo selection. Illumina offers a full

More information

Array Comparative Genomic Hybridisation (CGH)

Array Comparative Genomic Hybridisation (CGH) Array Comparative Genomic Hybridisation (CGH) Exceptional healthcare, personally delivered What is array CGH? Array CGH is a new test that is now offered to all patients referred with learning disability

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

Accelerate genomic breakthroughs in microbiology. Gain deeper insights with powerful bioinformatic tools.

Accelerate genomic breakthroughs in microbiology. Gain deeper insights with powerful bioinformatic tools. Accelerate genomic breakthroughs in microbiology. Gain deeper insights with powerful bioinformatic tools. Empowering microbial genomics. Extensive methods. Expansive possibilities. In microbiome studies

More information

Personalised Healthcare Frequently Asked Questions

Personalised Healthcare Frequently Asked Questions Personalised Healthcare Frequently Asked Questions Foreword In one sense, personalised healthcare is nothing new. It is what doctors have aimed to provide for their patients through the exercise of their

More information

Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2

Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2 August 2012 content 8 Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2 Maintaining fertility new opportunities in GENNET...3 Hysteroscopy without

More information

BG MEDICINE. Corporate Presentation February 2013

BG MEDICINE. Corporate Presentation February 2013 BG MEDICINE Corporate Presentation February 2013 CONFIDENTIAL Oct 9, 2007 Forward-Looking Statements This presentation contains forward-looking statements regarding future events or the future financial

More information

Innovators in Reproductive Genetics

Innovators in Reproductive Genetics ANEUPLOIDY DIAGNOSTICS DIAGNOSTICS EXCELLENCE 6182 DIAGNOSTICS PERFORMED OVER 10 YEARS OF EXPERIENCE PGS-NGS 360 PGD DIAGNOSIS SINCE 2005 TRANSLOCATION DIAGNOSIS NEXT GENERATION SEQUENCING Innovators in

More information

Exiqon continues to push the frontiers in the mirna field through our LNA technology. Henrik M. Pfundheller, Ph.D., VP Sales & Marketing

Exiqon continues to push the frontiers in the mirna field through our LNA technology. Henrik M. Pfundheller, Ph.D., VP Sales & Marketing Annual Report 2007 Exiqon continues to push the frontiers in the mirna field through our LNA technology Henrik M. Pfundheller, Ph.D., VP Sales & Marketing Exiqon at a glance Exiqon is a biotechnology company

More information

Today s Health Research Is Tomorrow s Healthcare

Today s Health Research Is Tomorrow s Healthcare Medical Research Charities Group La Touche House, 1 Grove Road, Dublin 6. Today s Health Research Is Tomorrow s Healthcare Medical Research Charities Group Pre-Budget Submission Budget 2011 The future

More information

Big Data jako součást našeho života. Zdenek Panec: June, 2015

Big Data jako součást našeho života. Zdenek Panec: June, 2015 Big Data jako součást našeho života Zdenek Panec: June, 2015 Agenda Big Data talk.. Primary Big Data Scenarios Big Data as Chance & Risk SAP HANA Platform 2013 SAP AG or an SAP affiliate company. All rights

More information